FDA Approved Products

1,302 products with lifecycle intelligence, competitive pressure scores, and patent timelines.

Type:AllNDABLAANDA
Lifecycle:GrowthPeakLOE ApproachingPost-LOELaunchPre-Launch
Sort:Approval DateNameCompetitive Pressure↓
Active:Lifecycle: PeakClear all
SKYCLARYS
omaveloxolone
Peak
Biogen
ORAL · CAPSULE
2023
NDA
0/100
SLYND
drospirenone
Peak
Xeltis
ORAL · TABLET
2019
NDA
0/100
SOAANZ
torsemide
Peak
ORAL · TABLET
2021
NDA
0/100
SODIUM NITRITE
sodium nitrite
Peak
Hope Pharmaceuticals
INTRAVENOUS · SOLUTION
2012
NDA
0/100
SODIUM THIOSULFATE
sodium thiosulfate
Peak
Hope Pharmaceuticals
INTRAVENOUS · SOLUTION
2012
NDA
0/100
SOLODYN
minocycline hydrochloride
Peak
Bausch + Lomb
ORAL · TABLET, EXTENDED RELEASE
2006
NDA
0/100
SOLOSEC
secnidazole
Peak
Evofem Biosciences
ORAL · GRANULE
2017
SMNDA
0/100
SOOLANTRA
ivermectin
Peak
Galderma
TOPICAL · CREAM
2014
NDA
0/100
SOTALOL HYDROCHLORIDE
sotalol hydrochloride
Peak
AltaThera Pharmaceuticals
INTRAVENOUS · SOLUTION
2009
NDA
0/100
SOTYKTU
deucravacitinib
Peak
Bristol Myers Squibb
ORAL · TABLET
2022
SMNDA
0/100
SOTYLIZE
sotalol hydrochloride
Peak
R-Pharm US
ORAL · SOLUTION
2014
NDA
0/100
SOVALDI
sofosbuvir
Peak
Gilead Sciences
ORAL · PELLETS
2019
SMNDA
0/100
SOVALDI
sofosbuvir
Peak
Gilead Sciences
ORAL · TABLET
2013
SMNDA
0/100
SPINRAZA
nusinersen
Peak
Biogen
INTRATHECAL · SOLUTION
2016
RNANDA
0/100
SPIRIVA RESPIMAT
tiotropium bromide inhalation spray
Peak
Boehringer Ingelheim
INHALATION · SPRAY, METERED
exacerbations in COPD patientschronic obstructive pulmonary disease+2
2014
NDA
0/100
SPRAVATO
esketamine hydrochloride
Peak
Johnson & Johnson
NASAL · SPRAY
depression
2019
NDA
0/100
SPRITAM
levetiracetam
Peak
ORAL · TABLET, FOR SUSPENSION
2015
NDA
0/100
SPY AGENT GREEN KIT
indocyanine green
Peak
INTRAVENOUS, INTERSTITIAL · POWDER
2018
NDA
0/100
STIVARGA
regorafenib
Peak
Bayer
ORAL · TABLET
oxaliplatin-irinotecan-based chemotherapy+7
2012
SMNDA
0/100
STRIBILD
elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate
Peak
Gilead Sciences
ORAL · TABLET
2012
NDA
0/100
SUBLOCADE
buprenorphine
Peak
Indivior
SUBCUTANEOUS · SOLUTION, EXTENDED RELEASE
2017
NDA
0/100
SUCCINYLCHOLINE CHLORIDE
succinylcholine chloride
Peak
Hikma
INTRAMUSCULAR, INTRAVENOUS · SOLUTION
2021
NDA
0/100
SUNLENCA
lenacapavir sodium
Peak
Gilead Sciences
SUBCUTANEOUS · SOLUTION
human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 whose current antiretroviral regimen is failing due to resistanceintolerance+2
2022
NDA
0/100
SUNLENCA
lenacapavir sodium
Peak
Gilead Sciences
ORAL · TABLET
human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 whose current antiretroviral regimen is failing due to resistanceintolerance+2
2022
NDA
0/100
← PreviousPage 47 of 55Next →